Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?

Is (BIIB) Outperforming Other Medical Stocks This Year?

    Has Biogen (BIIB) Outpaced Other Medical Stocks This Year?

    Is (BIIB) Outperforming Other Medical Stocks This Year?

      Pain Therapeutics' Shares Rally on Alzheimer's Study Grant

      Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.

        Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

        Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

          Sanghamitra Saha headshot

          Biotech ETFs in Focus on String of Q2 Earnings Beat

          Biotech ETFs draw attention post impressive Q2 results.

            PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

            PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.

              Nalak Das headshot

              S&P 500 Posts 5th Straight Weekly Gain: 5 Great Picks

              U.S. corporates have so far posted robust results for second-quarter 2018, maintaining the terrific earnings momentum which has begun since the first-quarter 2018.

                Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM

                Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM

                  5 Cheap PEG Stocks Suitable for GARP Investors

                  Although PEG is categorized under value investing, this strategy follows the principles of both growth and value investing.

                    Is a Beat in Store for Ionis (IONS) This Earnings Season?

                    On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.

                      Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit

                      Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

                        The Zacks Analyst Blog Highlights: Comcast, United Technologies, Biogen, Mondelez and Valero

                        The Zacks Analyst Blog Highlights: Comcast, United Technologies, Biogen, Mondelez and Valero

                          Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?

                          Is (BIIB) Outperforming Other Medical Stocks This Year?

                            Mark Vickery headshot

                            Top Analyst Reports for Comcast, United Technologies & Biogen

                            Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), United Technologies (UTX) and Biogen (BIIB).

                              Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT

                              Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.

                                Company News For Jul 25, 2018

                                Companies In The News are: HOG,BIIB,LLY,WHR

                                  Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More

                                  Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.

                                    Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug

                                    The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.

                                      Swarup Gupta headshot

                                      Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions

                                      Biotech stocks are largely resilient to trade related disruptions.

                                        Biogen (BIIB) Q2 Earnings & Sales Beat Estimates, Shares Up

                                        Biogen (BIIB) beats estimates on both counts in the second quarter. The company's multiple sclerosis drugs' sales up sequentially amid competition.

                                          Biogen (BIIB) Q2 Earnings Beat, Shares Up

                                          Biogen (BIIB) beat estimates both for earnings and sales in Q2. The company's oral MS drug Tecfidera sales decreased year over year.

                                            BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions

                                            Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.

                                              Madhu Goel headshot

                                              4 Biotech Bets to Watch as Industry Rebounds in a Month

                                              The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.

                                                Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

                                                On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance

                                                  AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.

                                                  AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.